January 21, 2010
It doesn’t employ a lot of people - just seven. But those employees invariably have M.D. or Ph.D. after their names. And their research is prized by their pharmaceutical and biotechnology clients.
How do I know?
For one thing, BioTrends has become one of the region’s fastest-growing privately held companies, with revenue growth of 160 percent between 2006 and 2008, according to the Wharton Small Business Development Center. Its 2008 revenues were $2.05 million.
And here’s another reason: A much larger company just bought it.
Decision Resources Inc. scooped up the six-year-old firm earlier this week, giving the Waltham, Mass., company something it did not have: A group focused on specialty pharmaceuticals, especially those used in nephrology, or kidney diseases.
Given that buyer and seller are both privately held, terms of the transaction were not disclosed.
Jason LaBonte, chief operating officer for portfolio planning and optimization of Decision Resources’ Biopharma business unit, said BioTrends will remain in Chester County.
BioTrends is the second Philadelphia-area company that Decision Resources has bought in about two years. It acquired Malvern’s Arlington Medical Resources Inc., which focuses on how hospitals use antibiotics and antifungals, at the end of 2007.
Return to In the News